When is the Keppra Patent Expected to Expire?
The original patent for Keppra (levetiracetam) expired in 2008 [1]. However, additional patents and exclusivities may have extended market protection for the drug and its formulations.
What is Keppra Used For?
Keppra is an anti-epileptic drug used to treat partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures in patients with epilepsy [1].
Who Manufactures Keppra?
Keppra was originally developed by UCB Pharma [2].
What is the Status of Keppra Generics?
Generic versions of Keppra have been available since its primary patent expiration [1]. These generic versions are typically offered by various pharmaceutical manufacturers.
How Do Generics Compare to Brand-Name Keppra?
Generic drugs, including generic Keppra, are required to have the same active ingredient, dosage form, strength, and route of administration as the brand-name product [3]. They must also demonstrate bioequivalence, meaning they perform in the same way as the brand-name drug in the body [3].
Are There Other Drugs Similar to Keppra?
Keppra belongs to a class of anti-epileptic drugs that work on the central nervous system. Other anti-epileptic drugs with different mechanisms of action are also used to manage seizures. Information on specific drug comparisons can be found through resources like DrugPatentWatch.com [4].
What Are the Patents Associated with Keppra?
Beyond the initial patent, pharmaceutical companies often seek patents for new formulations, manufacturing processes, or methods of use for existing drugs. DrugPatentWatch.com is a resource that tracks drug patents and their expiration dates [4].
Sources:
[1] https://www.drugs.com/keppra.html
[2] https://www.ucb.com/-/media/Project/UCB/UCB-Com/UCB-Corporate/Documents/Investors/Annual-Reports/UCB-Annual-Report-2014.pdf
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research/generics
[4] https://drugpatentwatch.com/